The HCT Frailty Scale is an easy prognostic tool composed of (a) Clinical Frailty Scale; (b) Instrumental Activities of Daily Living; (c) Timed-up-and-Go test; (d) Grip Strength; (e) Self-Health Rated Questionnaire;(f) Falls tests; (g) Albumin and C-reactive protein levels. This scale was designed to classify allogeneic hematopoietic cell transplant (alloHCT) candidates into t, pre-frail and frail groups, irrespective of age.This study evaluates the ability of this frailty classi cation to predict overall survival (OS) and nonrelapse mortality (NRM) in adult patients of all ages, in a prospective sample of 298 patients transplanted between 2018 and 2020. At rst consultation, 103 (34.6%) patients were t, 148 (49.7%) pre-frail, and 47 (15.8%) were frail. The 2-year OS and NRM of the three groups were 82.9%, 67.4%, and 48.3% (P<0.001), and 5.4%, 19.2%, and 37.7% (P<0.001). For patients younger than 60 years (n=174), the 2-year OS and NRM of t, pre-frail, and frail groups were 88.4%, 69,3% and 53.1% (P=0.002), and 5.8%, 22,8%, and 34.8% (P=0.005), respectively; and in patients older than 60 (n=124), OS and NRM were 75.5%, 63.8% and 41.4% (P=0.006), and 4.9%, 16.4%, and 42.1% (P=0.001). In conclusion, frailty predicted worse transplant outcomes in both younger and older adults.
HighlightsThe HCT Frailty Scale classi ed patients in t, pre-frail and frail groups, anticipating signi cant differences in OS and NRM across frailty groups.Frailty worsened transplant outcomes irrespective of patients' age, and the predictive power of the HCT Frailty Scale was comparable in adults younger and older than 60 years.